The analysis evaluated 95 confirmed Covid-19 infections among the 30,000 participants in the study. Moderna, which developed its vaccine in partnership with the National Institute for Allergy and Infectious Diseases, said 90 cases of Covid-19 were seen in the placebo group, up from 5 cases in the group that received its two-dose vaccine. This resulted in an estimated vaccine effectiveness of 94.5%.
The company’s shares rose more than 11% in premarket trading.
The announcement follows similar news from Pfizer’s late Covid-19 vaccine trial last week, as drug companies around the world race against the clock to find ways to prevent the virus, which affects more than 54, Has spread to 4 million people, killing more than 1.3 million.
“This is a pivotal moment in the development of our COVID-19 vaccine candidate,” Bancel said in a statement. “We have been tracking this virus since the beginning of January to protect as many people as possible around the world. We have known all along that every day is important. This positive interim analysis from our phase 3 study made us the first clinical analysis provides confirmation that our vaccine can prevent COVID-19 disease, including serious diseases. “
The Cambridge, Massachusetts-based company also said there were no “significant” safety concerns. The addition of the vaccine was generally safe and well tolerated, with most adverse events rated as mild or moderate in participants. Side effects included pain at the injection site and fatigue, muscle pain and headache after the second dose.
“To know that we have a vaccine that would help more people who would take it is just a wonderful feeling,” Bancel said in an interview with CNBC. “As you know, polls have shown a lot of people hesitating to take a vaccine because we are concerned about the politicization of a vaccine. They are concerned about what you get with a flu shot that you know is up to 50% 60% is effectiveness. “
With an efficacy rate of 95%, “I think that’s a cornerstone,” he said.
Investors expected ModernaThe vaccine is said to be highly effective afterwards Pfizer, another front runner in the Covid-19 vaccine, said so last week The vaccine was more than 90% effective. Moderna’s candidate, like that of the PfizerBioNTech Partnership uses messenger RNA or mRNA technology. It’s a new approach to vaccines that uses genetic material to trigger an immune response.
Moderna said Monday its vaccine was stable for up to 30 days at 36 to 46 degrees Fahrenheit, the temperature of a regular household or medical refrigerator. It can be stored at minus 4 degrees Fahrenheit for up to six months. In comparison, Pfizer’s vaccine requires a storage temperature of minus 94 degrees Fahrenheit.
Moderna told investors on October 29th that it was “actively preparing” for its potential vaccine launch worldwide, having completed registration for its study a week earlier. It is said that around 37% of the participants were from minority groups and 42% had other medical conditions or age groups that put them at high risk for serious illness. Men outweigh the number of women in the study by 53% to 47%.
Of the 95 Covid-19 cases, 20 participants were from “different” communities, including 12 Hispanic, four African-American, three Asian-American, and one multiracial.
Moderna plans to apply to the Food and Drug Administration for an emergency permit in the “coming weeks”. In the study, even after an application has been submitted, further data relevant to safety and effectiveness will be collected.
By the end of the year, Moderna expects around 20 million doses of the vaccine to be ready for shipping in the United States. The global production of 500 to 1 billion cans in 2021 is still on the right track.
The company has already signed supply contracts in North America, the Middle East and other regions of the world. It announced in August that it had reached an agreement with the US government Deliver 100 million doses of his vaccine. The deal gives the federal government the ability to purchase up to 400 million additional cans. The US had already invested $ 955 million in the development of Moderna’s Covid-19 vaccine, for a total investment of $ 2.48 billion.
In August, Moderna announced that some customers were being charged between $ 32 and $ 37 per dose for their vaccine at lower “pandemic prices”. The company said it was under discussion for larger volume agreements that will come at a lower price.
This is a developing story. Please try again.
– –CNBC’s Meg Tirrell contributed to this report.